Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

August 29, 2017

The more formal title should be: Randomized phase II results – lenalidomide is not a viable option post-allogeneic stem cell transplant for persistent chronic lymphocytic leukemia (CLL). So what does this mean? We know that a non-myeloablative Allogeneic Stem Cell Transplantation or allo-SCT offers a chance for a cure